Radosevich J A, Gould V E, Ma Y, Lee I, Thor A, Carney W P, Warren W H, Schlom J, Rosen S T
Northwestern University/Veterans Administration Lakeside Medical Center, Department of Medicine, Chicago, IL 60611.
Virchows Arch B Cell Pathol Incl Mol Pathol. 1989;56(6):377-83. doi: 10.1007/BF02890040.
In this study we examined 214 cases of primary human pulmonary neoplasms for the expression of a mutated form of the ras oncogene p21 product, recognized by the monoclonal antibody (MCA) DWP. Adjacent serial sections from these same cases had previously been used to demonstrate the frequency of ras p21 expression using the broadly reactive anti-ras p21 MCA RAP-5. Confirmation of the increased expression of p21 was accomplished using MCA Y13-259. The use of adjacent tissue sections from these cases allows the direct comparison of the expression of the mutated and non-mutated forms of ras p21. If reactivity with DWP would prove to be significantly more restrictive than that of the "pan" ras MCAs, RAP-5 and Y13-259, it would lend support to the possibility that DWP (and similar MCAs which detect other specific mutations) could be used to define subsets of these neoplasms based on their specific ras p21 phenotype. Since one would anticipate that the valine/cysteine substitution at position 12 of the ras p21 would occur at only low frequencies in human tumors, our results with DWP are consistent with this hypothesis. As previously reported, RAP-5 reacted with a high proportion of lung tumors (100/214 or 47%). In this report, we demonstrate the selective expression of the mutation recognized by the MCA DWP in only 5% of these same tumors (13/214), and that the expression of this mutated form is not restricted to any of the conventional histological subclasses of pulmonary neoplasms.
在本研究中，我们检测了214例原发性人类肺部肿瘤中由单克隆抗体（MCA）DWP识别的ras癌基因p21产物突变形式的表达情况。这些病例的相邻连续切片此前已用于使用广泛反应性的抗ras p21 MCA RAP-5来证明ras p21表达的频率。使用MCA Y13-259完成了p21表达增加的确认。使用这些病例的相邻组织切片可以直接比较ras p21突变形式和非突变形式的表达。如果与DWP的反应性被证明比“泛”ras MCA（RAP-5和Y13-259）的反应性明显更具限制性，这将支持DWP（以及检测其他特定突变的类似MCA）可用于根据其特定的ras p21表型定义这些肿瘤亚群的可能性。由于预计ras p21第12位的缬氨酸/半胱氨酸替代在人类肿瘤中仅以低频率发生，我们使用DWP的结果与该假设一致。如先前报道，RAP-5与高比例的肺肿瘤发生反应（100/214或47%）。在本报告中，我们证明MCA DWP识别的突变仅在这些相同肿瘤的5%（13/214）中选择性表达，并且这种突变形式的表达不限于任何传统的肺肿瘤组织学亚类。
